LungLife AI, Inc.
(the “Company” or “LungLife”)
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer announces its unaudited half-year report for the six months ended 30 June 2022.
Summary and Highlights (including post-period end):
Commenting on outlook, Paul Pagano, Chief Executive Officer of LungLife, said: “I am proud of the progress that the team has made over this six-month period. Our validation study is well underway, having enrolled our first participant in February, and we are where we expected to be at this time point to be able to complete enrolment by the end of Q1 2023.
“Beyond the continued enrolment of participants into the LungLB® validation study, over the remainder of the year we are focused on progressing towards commercial reimbursement. Following the grant of a CPT® PLA code in January, we now look ahead to the processes of pricing and coverage for the LungLB® test.”
Please click HERE for the full report.
"*" indicates required fields